• Our offerings
    • Market Access Strategy, HTA, and Health Economics
    • Nordic RWE & Evidence Generation
    • AI & Dashboard Solutions
    • Policy Shaping & Life Science Consulting
  • Our work
  • The latest
  • Our people
  • Careers
  • Contact us

DMP updates STA submission guidance

Updates on the use of AI in healthcare and digital health and care in the EU

Six new medicines were recommended by the Danish Medicines Council in June

NICE recommends cemiplimab for recurrent or metastatic cervical cancer

Palko has issued six new drug recommendations

Finland adopts most medicines with added value

TLV publishes new pricing and reimbursement guidelines

The Danish Medicines Council launches national basis list for GPs

First JCA report published for Ojemda

NICE recommends first new NHS treatment in over 20 years for women with resistant ovarian cancer

1 2 3 4 … 8 Next

Leveraging Nordic data & insights to support your Market Access goals.

NHTA Copenhagen
Nelson Mandelas Allé 14, 2450 Copenhagen SV, Denmark

NHTA Stockholm
Vasagatan 10, 5th floor, 111 20 Stockholm, Sweden

Contact us

+45 44 222 777
CVR: 39842882

+46 70-322 66 65
Org.nr: 559438-4207

contact@nhta.com

Navigation

  • Our offerings
  • Our work
  • The latest
  • Our people
  • Careers
  • Contact us

Follow us on LinkedIn

LinkedIn
  • Data Protection Policy
  • Cookie Policy